|
TIMM17A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.91499999968592E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.30079999999455E-06 |
| Normal-vs-Stage2 |
2.503700E-02 |
| Normal-vs-Stage3 |
9.4401000350075E-09 |
| Normal-vs-Stage4 |
8.68479999027727E-09 |
| Stage1-vs-Stage2 |
1.062180E-01 |
| Stage1-vs-Stage3 |
2.056400E-01 |
| Stage1-vs-Stage4 |
2.509900E-02 |
| Stage2-vs-Stage3 |
2.351700E-02 |
| Stage2-vs-Stage4 |
2.184300E-03 |
| Stage3-vs-Stage4 |
1.281800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.57219995197988E-09 |
| Normal-vs-AfricanAmerican |
4.003800E-03 |
| Normal-vs-Asian |
1.32350000003889E-06 |
| Caucasian-vs-AfricanAmerican |
3.476800E-01 |
| Caucasian-vs-Asian |
8.161000E-01 |
| AfricanAmerican-vs-Asian |
3.127600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.03640000026495E-07 |
| Normal-vs-Female |
5.05140000051085E-07 |
| Male-vs-Female |
1.779830E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.91199999949521E-07 |
| Normal-vs-Age(41-60Yrs) |
3.19229997991499E-09 |
| Normal-vs-Age(61-80Yrs) |
1.877730E-03 |
| Normal-vs-Age(81-100Yrs) |
2.741600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.128800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.283400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.271200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.634100E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.152830E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.342200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.783300E-03 |
| Classical-VS-Follicular |
1.201500E-03 |
| Classical-VS-Other |
1.212560E-01 |
| Classical-VS-Normal |
2.08420003477983E-09 |
| Tall-VS-Follicular |
4.3253999999493E-06 |
| Tall-VS-Other |
4.039800E-01 |
| Tall-VS-Normal |
8.25790547054339E-11 |
| Follicular-VS-Other |
3.720100E-02 |
| Follicular-VS-Normal |
7.048300E-02 |
| Other-VS-Normal |
1.423850E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.9190099999955E-05 |
| Normal-vs-N1 |
2.161100187692E-10 |
| N0-vs-N1 |
1.704360E-03 |
|
|
